Literature DB >> 17467356

Cyclooxygenase-2 gene disruption promotes proliferation of murine calvarial osteoblasts in vitro.

Zheng Xu1, Shilpa Choudhary, Yosuke Okada, Olga Voznesensky, Cynthia Alander, Lawrence Raisz, Carol Pilbeam.   

Abstract

Cyclooxygenase-2 (COX-2) is highly expressed in osteoblasts, and COX-2 produced prostaglandins (PGs) can increase osteoblastic differentiation in vitro. The goal of this study was to examine effects of COX-2 expression on calvarial osteoblastic proliferation and apoptosis. Primary osteoblasts (POBs) were cultured from calvariae of COX-2 wild-type (WT) and knockout (KO) mice. POB proliferation was evaluated by (3)H-thymidine incorporation and analysis of cell replication and cell cycle distribution by flow cytometry. POB apoptosis was evaluated by annexin and PI staining on flow cytometry. As expected, PGE(2) production and alkaline phosphatase (ALP) activity were increased in WT cultures compared to KO cultures. In contrast, cell numbers were decreased in WT compared to KO cells by day 4 of culture. Proliferation, measured on days 3-7 of culture, was 2-fold greater in KO than in WT POBs and associated with decreased Go/G1 and increased S cell cycle distribution. There was no significant effect of COX-2 genotype on apoptosis under basal culture conditions on day 5 of culture. Cell growth was decreased in KO POBs by the addition of PGE(2) or a protein kinase A agonist and increased in WT POBs by the addition of NS398, a selective COX-2 inhibitor. In contrast, differentiation and cell growth in marrow stromal cell (MSC) cultures, evaluated by ALP and crystal violet staining respectively, were increased in MSCs from WT mice compared to MSCs from KO mice, and exogenous PGE(2) increased cell growth in KO MSC cultures. We conclude that PGs secondary to COX-2 expression decrease osteoblastic proliferation in cultured calvarial cells but increase growth of osteoblastic precursors in MSC cultures.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17467356      PMCID: PMC1993538          DOI: 10.1016/j.bone.2007.03.009

Source DB:  PubMed          Journal:  Bone        ISSN: 1873-2763            Impact factor:   4.398


  61 in total

1.  Knockout of the murine prostaglandin EP2 receptor impairs osteoclastogenesis in vitro.

Authors:  X Li; Y Okada; C C Pilbeam; J A Lorenzo; C R Kennedy; R M Breyer; L G Raisz
Journal:  Endocrinology       Date:  2000-06       Impact factor: 4.736

2.  Impaired bone resorption to prostaglandin E2 in prostaglandin E receptor EP4-knockout mice.

Authors:  C Miyaura; M Inada; T Suzawa; Y Sugimoto; F Ushikubi; A Ichikawa; S Narumiya; T Suda
Journal:  J Biol Chem       Date:  2000-06-30       Impact factor: 5.157

3.  Stimulation of bone formation and prevention of bone loss by prostaglandin E EP4 receptor activation.

Authors:  Keiji Yoshida; Hiroji Oida; Takuya Kobayashi; Takayuki Maruyama; Masaharu Tanaka; Teruaki Katayama; Kojiro Yamaguchi; Eri Segi; Tadao Tsuboyama; Mutsumi Matsushita; Kosei Ito; Yoshiaki Ito; Yukihiko Sugimoto; Fumitaka Ushikubi; Shuichi Ohuchida; Kigen Kondo; Takashi Nakamura; Shuh Narumiya
Journal:  Proc Natl Acad Sci U S A       Date:  2002-03-26       Impact factor: 11.205

Review 4.  Function of prostanoid receptors: studies on knockout mice.

Authors:  Takuya Kobayashi; Shuh Narumiya
Journal:  Prostaglandins Other Lipid Mediat       Date:  2002-08       Impact factor: 3.072

Review 5.  The enzymology of prostaglandin endoperoxide H synthases-1 and -2.

Authors:  William L Smith; Inseok Song
Journal:  Prostaglandins Other Lipid Mediat       Date:  2002-08       Impact factor: 3.072

6.  Bone biomechanical properties in prostaglandin EP1 and EP2 knockout mice.

Authors:  M P Akhter; D M Cullen; G Gong; R R Recker
Journal:  Bone       Date:  2001-08       Impact factor: 4.398

Review 7.  Nuclear prostaglandin signaling system: biogenesis and actions via heptahelical receptors.

Authors:  Fernand Gobeil; Alejandro Vazquez-Tello; Anne Marilise Marrache; Mosumi Bhattacharya; Daniella Checchin; Ghassan Bkaily; Pierre Lachapelle; Alfredo Ribeiro-Da-Silva; Sylvain Chemtob
Journal:  Can J Physiol Pharmacol       Date:  2003-02       Impact factor: 2.273

8.  Bone morphogenetic protein 2 induces cyclo-oxygenase 2 in osteoblasts via a Cbfal binding site: role in effects of bone morphogenetic protein 2 in vitro and in vivo.

Authors:  Daichi Chikazu; Xiaodong Li; Hiroshi Kawaguchi; Yoko Sakuma; Olga S Voznesensky; Douglas J Adams; Manshan Xu; Kazuto Hoshio; Vedran Katavic; Harvey R Herschman; Lawrence G Raisz; Carol C Pilbeam
Journal:  J Bone Miner Res       Date:  2002-08       Impact factor: 6.741

9.  Cyclo-oxygenase 2 function is essential for bone fracture healing.

Authors:  Ann Marie Simon; Michaele Beth Manigrasso; J Patrick O'Connor
Journal:  J Bone Miner Res       Date:  2002-06       Impact factor: 6.741

10.  Prostaglandin E2 induced functional expression of early growth response factor-1 by EP4, but not EP2, prostanoid receptors via the phosphatidylinositol 3-kinase and extracellular signal-regulated kinases.

Authors:  Hiromichi Fujino; Wei Xu; John W Regan
Journal:  J Biol Chem       Date:  2003-02-03       Impact factor: 5.157

View more
  12 in total

1.  Basal bone phenotype and increased anabolic responses to intermittent parathyroid hormone in healthy male COX-2 knockout mice.

Authors:  Manshan Xu; Shilpa Choudhary; Olga Voznesensky; Qi Gao; Douglas Adams; Vilmaris Diaz-Doran; Qian Wu; David Goltzman; Lawrence G Raisz; Carol C Pilbeam
Journal:  Bone       Date:  2010-05-13       Impact factor: 4.398

2.  Osteoblast differentiation profiles define sex specific gene expression patterns in craniosynostosis.

Authors:  Sarah S Park; Richard P Beyer; Matthew D Smyth; Christine M Clarke; Andrew E Timms; Theo K Bammler; Brendan D Stamper; Brigham H Mecham; Jennifer A Gustafson; Michael L Cunningham
Journal:  Bone       Date:  2015-03-07       Impact factor: 4.398

Review 3.  Fracture healing and lipid mediators.

Authors:  J Patrick O'Connor; Michaele B Manigrasso; Brian D Kim; Sangeeta Subramanian
Journal:  Bonekey Rep       Date:  2014-04-02

4.  Low dose aspirin therapy decreases blood glucose levels but does not prevent type i diabetes-induced bone loss.

Authors:  Lindsay M Coe; Jeffery D Denison; Laura R McCabe
Journal:  Cell Physiol Biochem       Date:  2011-12-15

5.  Age-related changes in bone morphology are accelerated in group VIA phospholipase A2 (iPLA2beta)-null mice.

Authors:  Sasanka Ramanadham; Kevin E Yarasheski; Matthew J Silva; Mary Wohltmann; Deborah Veis Novack; Blaine Christiansen; Xiaolin Tu; Sheng Zhang; Xiaoyong Lei; John Turk
Journal:  Am J Pathol       Date:  2008-03-18       Impact factor: 4.307

6.  Effect of deletion of the prostaglandin EP2 receptor on the anabolic response to prostaglandin E2 and a selective EP2 receptor agonist.

Authors:  Shilpa Choudhary; Cynthia Alander; Peili Zhan; Qi Gao; Carol Pilbeam; Lawrence Raisz
Journal:  Prostaglandins Other Lipid Mediat       Date:  2008-02-29       Impact factor: 3.072

7.  Anabolic effects of PTH in cyclooxygenase-2 knockout osteoblasts in vitro.

Authors:  Shilpa Choudhary; Hechang Huang; Lawrence Raisz; Carol Pilbeam
Journal:  Biochem Biophys Res Commun       Date:  2008-05-21       Impact factor: 3.575

8.  The effects of low dose X-irradiation on osteoblastic MC3T3-E1 cells in vitro.

Authors:  Wei Xu; Lan Xu; Ming Chen; Yong Tao Mao; Zong Gang Xie; Shi Liang Wu; Qi Rong Dong
Journal:  BMC Musculoskelet Disord       Date:  2012-06-08       Impact factor: 2.362

Review 9.  Deregulation of bone forming cells in bone diseases and anabolic effects of strontium-containing agents and biomaterials.

Authors:  Shuang Tan; Binbin Zhang; Xiaomei Zhu; Ping Ao; Huajie Guo; Weihong Yi; Guang-Qian Zhou
Journal:  Biomed Res Int       Date:  2014-03-31       Impact factor: 3.411

10.  Prostaglandin E2 acts via bone marrow macrophages to block PTH-stimulated osteoblast differentiation in vitro.

Authors:  Shilpa Choudhary; Katherine Blackwell; Olga Voznesensky; Abhijit Deb Roy; Carol Pilbeam
Journal:  Bone       Date:  2013-04-29       Impact factor: 4.398

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.